Acadia looks to next schizophrenia readout after Phase III miss

Acadia shed $3.96 (15%) to $22.01 in after hours trading Monday when it reported after market close that Nuplazid pimavanserin as an adjunct schizophrenia therapy missed the primary endpoint and key secondary endpoint in the Phase III ENHANCE trial.

The readout from the 396-patient trial in patients with moderate-to-severe pyschotic symptoms was one of two for Nuplazid from Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) that International Biotechnology Trust’s Ailsa Craig told BioCentury she watching for this quarter in BioCentury’s 3Q19 Financial Preview (see “All Eyes on New Modality Launches, Cancer and Rare Disease Data in 3Q19”)...